Eli Lilly & Co. Ltd

Eli Lilly & Co. Ltd. is the UK arm of the research-based pharmaceutical company (Eli Lilly & Co.) with its headquarters located in Indianapolis, Indiana, U.S.A. The company has approximately 41,000 employees worldwide with more than 8,000 employees engaged in research and development. Research and development facilities are located in six countries, with clinical research conducted in more than 55 countries. The Erl Wood facility in the UK is Lilly’s largest R&D facility outside of the United States and is a centre of Excellence for Neuroscience and Neurodegeneration research.

Key staff involved in EBiSC

Hugh Nuthall (Research Advisor) – Neuroscience Therapeutic Area. Hugh holds a D.Phil in Molecular Medicine from the University of Oxford and joined Eli Lilly in 2009 where he is a Team Leader in the Molecular Pathology Group at the Lilly Research Centre, Erl Wood, UK. The current research focus of the team is on understanding mechanisms and identifying molecules that modulate misfolded proteins associated with Alzheimer’s and other Neurodegenerative diseases.

Dr. Daniel Ursu (Principal Research Scientist) – Daniel holds a PhD in Cell physiology and joined Lilly in 2006. His background is in electrophysiology and cellular imaging and worked previously in the pain and psychiatric disease areas. The current research focus of his team is on developing novel neuronal iPS models of Alzheimer’s disease.

More information: http://www.lilly.com »